Patents by Inventor Jose Ángel Morales García

Jose Ángel Morales García has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS
    Publication number: 20230330063
    Abstract: Combination product for the treatment of neurological and/or psychiatric disorders The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.
    Type: Application
    Filed: June 21, 2023
    Publication date: October 19, 2023
    Inventors: Ana Maria Perez Castillo, Jordi Riba Serrano, Jose Angel Morales Garcia
  • Combination product for the treatment of neurological and/or psychiatric disorders
    Patent number: 11723894
    Abstract: The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: August 15, 2023
    Assignee: TERRAN BIOSCIENCES, INC.
    Inventors: Ana Maria Perez Castillo, Jordi Riba Serrano, Jose Ángel Morales García
  • COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS
    Publication number: 20200397752
    Abstract: The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.
    Type: Application
    Filed: October 26, 2018
    Publication date: December 24, 2020
    Applicants: Consejo Superior de Investigacions Cientificas (CSIS), Universidad Autonoma de Madrid, Centro de Investigacion Biomedica en Red de Enformedadas Neurodegerativas, Blumentech, S.L., Institute de Recerca de L'Hospital de la Santa Creu I Sant Pau
    Inventors: Ana Maria Perez Castillo, Jordi Riba Serra-No, Jose Angel Morales Garcia